Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma: early-phase trial registry

1 of 1 indexed p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma: 1 US clinical trial tracked, 1 recruiting.

p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is ECOG-ACRIN Cancer Research Group, running 1 of these trials.

Enrollment posture brief

Registry condition p16ink4a-negative-oropharyngeal-squamous-cell-carcinoma

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

p16INK4a Negative Oropha (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma

p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Top Sponsors

Named interventions

Most-linked intervention names on p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Intensity-Modulated Radiation Therapy Radiation
1 trials
Laboratory Biomarker Analysis Other
1 trials
Cisplatin Drug
1 trials

US sites by state

Facility locations filed on p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma trials. A trial with sites in several states counts in each.

California 1 trials
Arizona 1 trials
Arkansas 1 trials
Alabama 1 trials
Alaska 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • ECOG-ACRIN Cancer Research Group sponsors the most p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma trials on record, review their full trial history before evaluating a specific study. See ECOG-ACRIN Cancer Research Group's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma condition card totals 1 registered trials; most-linked intervention Intensity-Modulated Radiation Therapy; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.